Real-World Value of Direct-Acting Antivirals for Hepatitis C at Kaiser Permanente Southern California
This analysis demonstrates value and innovation of direct-acting antivirals for the treatment of chronic hepatitis C in the US Kaiser Permanente health system.
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score
Guselkumab Shows Sustained Efficacy in Phase 3b APEX Study for Active PsA
Baseline LTF Linked With Treatment Response in SCLC
Immune Microenvironment a Key Target in CLL